HC Wainwright's Rating of Intellia Therapeutics on 3/5/2025

On March 5, 2025, HC Wainwright updated its outlook on Intellia Therapeutics (NASDAQ:NTLA) with the action "Initiated Coverage", setting a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from HC Wainwright

DateCompanyAction
11/20/2026
Plug Power, Inc. stock logo
PLUG
Plug Power
Reiterated Rating
11/20/2026
Savara Inc. stock logo
SVRA
Savara
Lower Price Target
11/20/2026
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
Reiterated Rating
11/20/2026
Tvardi Therapeutics, Inc. stock logo
TVRD
Tvardi Therapeutics
Reiterated Rating
11/20/2026
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Lower Price Target
11/20/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Reiterated Rating
More Ratings From HC Wainwright